Home ASCO 2026: Lorlatinib Shows Unprecedented 7-Year Results — 55% of Advanced NSCLC Patients Remain Progression-Free, Median PFS Expected to Reach 10 Years

ASCO 2026: Lorlatinib Shows Unprecedented 7-Year Results — 55% of Advanced NSCLC Patients Remain Progression-Free, Median PFS Expected to Reach 10 Years

May 30, 2026 13:32 CST Updated 15:46